Andrew Martin

Professor of Biostatistics

University of Sydney

Australia

Research Interests

Explore related searches

Professors in Australia Professors in Medical Imaging Medical Imaging professors in Australia

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Andrew Martin is a Professor of Biostatistics at the University of Sydney, Australia. His research focuses on biostatistical methodologies applied to oncology, particularly in the context of prostate cancer and other malignancies. Recent articles include studies on treatment outcomes in metastatic hormone-sensitive prostate cancer and the efficacy of new therapies for advanced gastric cancer.

Articles (27)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Garvan Institute of Medical Research

AUSTRALIA

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Andrew Martin

Research Interests

Explore related searches

Contact this professor

About

Articles (27)

Association of the circulating lipid panel, PCPro, with clinical outcomes in metastatic hormone-sensitive prostate cancer: post hoc analysis of the ENZAMET phase III randomised trial (ANZUP 1304)

Oncologist and General Practitioner Perspectives of Shared Care for Colorectal Cancer Survivors

INTEGRATE pooled phase 2/3 results are robust to postprogression switching and the winner’s curse

Balancing precision and affordability in assessing infant development in large-scale mortality trials: secondary analysis of a randomised controlled trial

Enzalutamide with standard first-line therapy for metastatic hormone-sensitive prostate cancer: a plain language summary of the ENZAMET trial (ANZUP 1304)

INTEGRATE IIa Phase III Study: Regorafenib for Refractory Advanced Gastric Cancer

Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p)

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP)

[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Validation of Prognostic and Predictive Models for Therapeutic Response in Patients Treated with [<sup>177</sup>Lu]Lu-PSMA-617 Versus Cabazitaxel for Metastatic Castration-resistant Prostate Cancer (TheraP): A Post Hoc Analysis from a Randomised, Open-label, Phase 2 Trial.

Colorectal cancer survivors' experiences and views of shared and telehealth models of survivorship care: A qualitative study

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial

Correction to: Using three scenarios to explain life expectancy in advanced cancer: attitudes of patients, family members, and other healthcare professionals (Supportive Care in Cancer, (2022), 30, 9, (7763-7772), 10.1007/s00520-022-07167-3)

INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)

Accuracy of oncologists’ estimates of expected survival time in advanced cancer

Evaluation of <sup>177</sup>Lu-PSMA SPECT Quantitation as a Response Biomarker within a Prospective <sup>177</sup>Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN)

PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP)

DASL-HiCaP: Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801). a randomized phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

ENZA-p: A randomized phase II trial using PSMA as a therapeutic agent and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Effects of delayed versus immediate umbilical cord clamping in reducing death or major disability at 2 years corrected age among very preterm infants (APTS): a multicentre, randomised clinical trial

Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP

INTEGRATE IIb: A randomized phase III open label study of regorafenib plus nivolumab versus standard chemotherapy in refractory advanced gastroesophageal cancer (AGOC)

PSMA PET and FDG PET as predictors of response and prognosis in a randomized phase 2 trial of Lu-177-PSMA-617 (LuPSMA) versus cabazitaxel in metastatic, castration-resistant prostate cancer (mCRPC) progressing after docetaxel (TheraP ANZUP 1603)

Quantifying molecular imaging patterns of treatment response or progression using a novel traffic light workflow within a prospective phase I/II trial of 1(77)LuPSMA-617 and NOX66 (LuPIN)

SUB-urothelial durvalumab injection: 1 (SUBDUE-1)-Results from the first nine urothelial cancer patients using a dose-escalation schedule

Collaborators (9)

Andrew Redfern

Anna Lene Seidler

Alison Zhang

Deborah Schofield

Andrew Nguyen

Raymond Chan

Yu Yang Soon

Roslyn Francis

Tahlia Scheinberg

Make your next move.